Choi D.W.,Korea Institute of Science and Technology |
Armitage R.,Eli Lilly and Company |
Brady L.S.,U.S. National Institutes of Health |
Coetzee T.,National Multiple Sclerosis Society |
And 7 more authors.
Neuron | Year: 2014
Several large pharmaceutical companies have selectively downsized their neuroscience research divisions, reflecting a growing view that developing drugs to treat brain diseases is more difficult and often more time-consuming and expensive than developing drugs for other therapeutic areas, and thus represents a weak area for investment. These withdrawals reduce global neuroscience translational capabilities and pose a serious challenge to society's interests in ameliorating the impact of nervous system diseases. While the path forward ultimately lies in improving understandings of disease mechanisms, many promising therapeutic approaches have already been identified, and rebalancing the underlying risk/reward calculus could help keep companies engaged in making CNS drugs. One way to do this that would not require upfront funding is to change the policies that regulate market returns for the most-needed breakthrough drugs. The broader neuroscience community including clinicians and patients should convene to develop and advocate for such policy changes. © 2014 Elsevier Inc.
PubMed | University of Minnesota, The Michael J Fox Foundation For Parkinsons Research, University of Chicago, University of Rochester and 7 more.
Type: Journal Article | Journal: Movement disorders : official journal of the Movement Disorder Society | Year: 2016
Identifying PD-specific biomarkers in biofluids will greatly aid in diagnosis, monitoring progression, and therapeutic interventions. PD biomarkers have been limited by poor discriminatory power, partly driven by heterogeneity of the disease, variability of collection protocols, and focus on de novo, unmedicated patients. Thus, a platform for biomarker discovery and validation in well-characterized, clinically typical, moderate to advanced PD cohorts is critically needed.BioFIND (Fox Investigation for New Discovery of Biomarkers in Parkinsons Disease) is a cross-sectional, multicenter biomarker study that established a repository of clinical data, blood, DNA, RNA, CSF, saliva, and urine samples from 118 moderate to advanced PD and 88 healthy control subjects. Inclusion criteria were designed to maximize diagnostic specificity by selecting participants with clinically typical PD symptoms, and clinical data and biospecimen collection utilized standardized procedures to minimize variability across sites.We present the study methodology and data on the cohorts clinical characteristics. Motor scores and biospecimen samples including plasma are available for practically defined off and on states and thus enable testing the effects of PD medications on biomarkers. Other biospecimens are available from off state PD assessments and from controls.Our cohort provides a valuable resource for biomarker discovery and validation in PD. Clinical data and biospecimens, available through The Michael J. Fox Foundation for Parkinsons Research and the National Institute of Neurological Disorders and Stroke, can serve as a platform for discovering biomarkers in clinically typical PD and comparisons across PDs broad and heterogeneous spectrum. 2016 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
News Article | November 29, 2016
NEW YORK and SAN FRANCISCO, Nov. 29, 2016 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research (MJFF) announces Duygu Tosun-Turgut, PhD, assistant professor of radiology and biomedical imaging at UC San Francisco and co-director of the Center for Imaging of...
Sherer T.B.,The Michael J Fox Foundation For Parkinsons Research |
Chowdhury S.,The Michael J Fox Foundation For Parkinsons Research |
Peabody K.,The Michael J Fox Foundation For Parkinsons Research |
Brooks D.W.,The Michael J Fox Foundation For Parkinsons Research
Movement Disorders | Year: 2012
Improved symptomatic and disease-modifying treatments are needed for Parkinson's disease (PD). Although significant advances have been made in the understanding of PD etiology, the translation of these discoveries into novel transformative therapies has been limited as a result of systemic challenges in PD drug development. Preclinical testing lacks clear standards and prioritization criteria for advancing therapies to the clinic. Clinical testing is marked by expensive, long, and uninformative studies. In parallel to these scientific challenges, funding of late-stage drug development has become increasingly scarce and risk averse. In this context, novel models of collaboration and funding are opening up new avenues for pursuing treatments. This review will discuss the most critical challenges in PD drug development and the innovative approaches being developed to overcome these hurdles. © 2012 Movement Disorder Society.
Ko W.K.D.,Motac Neuroscience Ltd |
Ko W.K.D.,Institut Universitaire de France |
Ko W.K.D.,French National Center for Scientific Research |
Pioli E.,Motac Neuroscience Ltd |
And 8 more authors.
Movement Disorders | Year: 2014
Amantadine, an N-methyl-D-aspartate glutamate receptor antagonist, is currently the only pharmacological treatment for levodopa-induced dyskinesia (LID) in Parkinson's disease (PD), but causes adverse effects on the central nervous system at therapeutic doses. Fenobam, a negative modulator of metabotropic glutamate receptor subtype 5, has recently been reported to attenuate LID in MPTP-treated macaques. The aim of the current study was to investigate the treatment interactions of fenobam and amantadine on LID in the MPTP-treated macaque model of PD. The antidyskinetic and -parkinsonian effects were measured after administration of fenobam (10-30 mg/kg) and amantadine (10-30 mg/kg) alone and in combination. Fenobam (30 mg/kg) and amantadine (30 mg/kg) alone reduced LID, whereas lower doses of either drug did not cause any significant effects. A combined treatment of fenobam and amantadine at subthreshold doses (10 and 20 mg/kg) significantly reduced LID without worsening PD disability. These data suggest that a low-dose combination of fenobam and amantadine can be used for alleviating dyskinesia without causing adverse motor effects. Such combined therapies may offer a new therapeutic strategy for treatment of LID in PD patients. © 2014 International Parkinson and Movement Disorder Society.
PubMed | Washington University in St. Louis, Van Andel Research Institute, The Michael J Fox Foundation For Parkinsons Research, University of Illinois at Chicago and 6 more.
Type: Journal Article | Journal: Journal of Parkinson's disease | Year: 2016
Recent research suggests that in Parkinsons disease the long, thin and unmyelinated axons of dopaminergic neurons degenerate early in the disease process. We organized a workshop entitled Axonal Pathology in Parkinsons disease, on March 23rd, 2016, in Cleveland, Ohio with the goals of summarizing the state-of-the-art and defining key gaps in knowledge. A group of eight research leaders discussed new developments in clinical pathology, functional imaging, animal models, and mechanisms of degeneration including neuroinflammation, autophagy and axonal transport deficits. While the workshop focused on PD, comparisons were made to other neurological conditions where axonal degeneration is well recognized.
News Article | November 28, 2016
JERUSALEM, November 28, 2016 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces it has entered into an agreement with the Michael J. Fox...
News Article | November 15, 2016
NEW YORK, Nov. 15, 2016 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research (MJFF) announces that Susan Bressman, MD, chair of the Department of Neurology at Mount Sinai Beth Israel, and Laurie Ozelius, PhD, associate neuroscientist and associate professor of...
News Article | November 15, 2016
NEW YORK, Nov. 15, 2016 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research (MJFF) has conferred the 2016 Robert A. Pritzker Prize for Leadership in Parkinson's Research to Ira Shoulson, MD, professor of neurology, pharmacology and human science and director...
News Article | February 28, 2017
WASHINGTON, Feb. 28, 2017 /PRNewswire-USNewswire/ -- As part of The Michael J. Fox Foundation for Parkinson's Research (MJFF) 2017 Parkinson's Policy Forum, Michael J. Fox met with bipartisan members of the House of Representatives today to urge lawmakers to support policies that...